Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
46 studies found for:    "Membranous nephropathy"
Show Display Options
Rank Status Study
21 Completed To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)
Condition: Membranous Nephropathy
Intervention: Drug: TW
22 Completed Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy
Condition: Idiopathic Membranous Nephropathy
Intervention: Drug: Tacrolimus
23 Completed Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid
Condition: Idiopathic Membranous Nephropathy
Interventions: Drug: Tripterygium wilfordii;   Drug: FK506
24 Not yet recruiting Study on the Therapeutic Effect of TCM Treatment for MDR MN
Condition: Idiopathic Membranous Nephropathy
Intervention: Drug: Jianpixiaozhong particles and Wuse Dietotherapy
25 Recruiting Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Conditions: Nephrotic Syndrome;   Proteinuria;   Autoimmune Disease;   Glomerular Disease;   Membranous Glomerulonephritis
Interventions: Drug: Rituximab Infusion;   Drug: Oral Cyclosporine
26 Completed Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy
Conditions: Membranous Glomerulonephritis;   Lupus Membranous Nepropathy
Intervention: Drug: Sirolimus
27 Recruiting Nephrotic Syndrome Study Network
Conditions: Minimal Change Disease (MCD);   Membranous Nephropathy;   Glomerulosclerosis, Focal Segmental
28 Active, not recruiting Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG)
Condition: Nephrotic Syndrome Secondary to Idiopathic Membranous Glomerulonephritis
Interventions: Drug: tacrolimus;   Drug: tacrolimus and mycophenolate mofetil
29 Terminated Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: TRU-015
30 Unknown  Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation
Condition: Kidney Transplantation
Intervention: Other: Anticorps anti-PLA2R1
31 Unknown  A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy
Condition: Glomerulonephritis
Intervention: Drug: Adrenocorticotrophic hormone ACTH
32 Unknown  Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
Conditions: Glomerulonephritis, Membranous;   Neonatal Diseases and Abnormalities;   Hemochromatosis
33 Recruiting Immune System Related Kidney Disease
Conditions: Glomerulonephritis;   Lupus Nephritis;   Membranous Glomerulonephritis;   Autoimmune Disease;   Nephrotic Syndrome
34 Active, not recruiting
Has Results
A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Condition: Glomerulonephritis, Membranous
Intervention: Drug: belimumab
35 Terminated
Has Results
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Conditions: Proteinuric Kidney Disease;   Diabetic Nephropathy;   Hypertensive Nephrosclerosis;   IgA Nephropathy;   Focal Segmental Glomerulosclerosis;   Glomerulopathy (Obesity-associated);   Glomerulonephritis, Membranous
Interventions: Drug: Aliskiren;   Drug: Valsartan
36 Completed A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis
Conditions: Lupus Nephritis;   Glomerulonephritis, Membranous
Interventions: Drug: prednisolone and mycophenolate mofetil;   Drug: prednisolone and tacrolimus
37 Completed Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection
Conditions: Hepatocellular Carcinoma;   Hepatitis B
Interventions: Procedure: PEIT;   Procedure: TOCE;   Procedure: TOCE plus PEIT;   Procedure: TOCE plus RFA;   Dietary Supplement: MGN-3;   Drug: Entecavir
38 Recruiting Phase I Study of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Conditions: Advanced Cancers;   Melanoma
Interventions: Drug: MGN1703;   Drug: Ipilimumab
39 Active, not recruiting Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
Condition: Small Cell Lung Cancer
Interventions: Drug: MGN1703;   Other: Standard of care
40 Completed Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV
Condition: Hepatitis C, Chronic
Interventions: Drug: pegylated IFN;   Dietary Supplement: Biobran;   Drug: Ribavirin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-46) Show next page of results    Last Page
Indicates status has not been verified in more than two years